Daniel Joseph Apel
Known title: Chief Financial OfficerCIK: 0002081169
Associated companies
Transaction History
| ARWR | ▼ Sell | Open Market | 3,208 | $225K | 4/22/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 1,157 | $82K | 4/22/2026 | View on chart |
| ARWR | ▼ Sell | Open Market | 8,730 | $628K | 4/22/2026 | View on chart |
| ARWR | ▲ Buy | Grant | 75,000 | $0 | 1/6/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value
Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.
Arrowhead to Share Alzheimer's Data; Analyst Notes Voucher Value. Arrowhead Pharmaceuticals announced it will host a webinar to present interim clinical data from a Phase 1/2a study of ARO-MAPT for Alzheimer’s disease. Separately, a Seeking Alpha article discussed the financial implications of a $215 million voucher, framing it within the context of fast-follower strategies. The stock is currently trading near its 52-week low, with an RSI of 29.8 indicating oversold conditions.